+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Complete remissions in afatinib-treated non-small-cell lung cancer patients with symptomatic brain metastases

Complete remissions in afatinib-treated non-small-cell lung cancer patients with symptomatic brain metastases

Anti-Cancer Drugs 27(9): 914-915

In patients with non-small-cell lung cancer, the presence of brain metastases requires specific treatment due to the unfavourable overall impact of these lesions. Treatment with the tyrosine kinase inhibitor afatinib was shown to induce complete and long-lasting remissions in the five patients described here. All of them had multiple brain lesions and presented with symptoms. Study evidence suggests beneficial effects of afatinib in this respect, underlining these clinical observations. Afatinib might be incorporated into current treatment algorithms, allowing for the omission of radiotherapy, provided that larger phase III trials confirm the potential of epidermal growth factor receptor tyrosine kinase inhibitors in this respect.

(PDF emailed within 0-6 h: $19.90)

Accession: 057477867

Download citation: RISBibTeXText

PMID: 27442131

DOI: 10.1097/CAD.0000000000000410

Related references

Is afatinib a treatment option for brain metastases in patients with EGFR mutation-positive non-small cell lung cancer?. Annals of Translational Medicine 4(11): 225, 2016

Randomized Phase II Study of Afatinib Plus Simvastatin Versus Afatinib Alone in Previously Treated Patients with Advanced Nonadenocarcinomatous Non-small Cell Lung Cancer. Cancer Research and Treatment 49(4): 1001-1011, 2017

Complete Remission of Brain Metastases in Non-Small Cell Lung Cancer Patients Harboring an EGFR Mutation Treated with Tyrosine Kinase Inhibitor without Radiotherapy: A Report of 3 Cases. Case Reports in Oncology 7(1): 149-154, 2014

First-Line Afatinib versus Chemotherapy in Patients with Non-Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases. Journal of Thoracic Oncology 11(3): 380-390, 2017

A second-line therapy with topotecan in patients with small cell lung cancer with symptomatic brain metastases. Annals of Hematology 77(SUPPL 2): S223, 1998

Intracranial Responses to Afatinib at Different Doses in Patients With EGFR-mutated Non-small-cell Lung Carcinoma and Brain Metastases. Clinical Lung Cancer 2019, 2019

Brain Metastases in Patients with Limited Small Cell Lung Cancer Achieving Complete Remission. Chest Journal 96(6): 1332-1335, 1989

Afatinib-refractory brain metastases from EGFR-mutant non-small-cell lung cancer successfully controlled with erlotinib: a case report. Anti-Cancer Drugs 27(3): 251-253, 2016

Outcome of surgical resection of symptomatic cerebral lesions in non-small cell lung cancer patients with multiple brain metastases. Brain Tumor Research and Treatment 1(2): 64-70, 2014

Efficacy of the irreversible ErbB family blocker afatinib in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-pretreated non-small-cell lung cancer patients with brain metastases or leptomeningeal disease. Journal of Thoracic Oncology 10(1): 156-163, 2015

Cranial irradiation for preventing brain metastases of small cell lung cancer in patients in complete remission. Cochrane Database of Systematic Reviews: Cd002805-Cd002805, 2000

Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial. Annals of Oncology 27(3): 417-423, 2016

Outcome and prognostic factors in patients with brain metastases from small-cell lung cancer treated with whole brain radiotherapy. Journal of Neuro-Oncology 134(1): 205-212, 2017

Clinical analysis of patients treated with afatinib for advanced non-small cell lung cancer: A Nagano Lung Cancer Research Group observational study. Respiratory Investigation 54(6): 462-467, 2017

Clinical analysis of EGFR-positive non-small cell lung cancer patients treated with first-line afatinib: A Nagano Lung Cancer Research Group. Thoracic Cancer 2019, 2019